* Drug tested in 1,250 high-risk patients over 30 days
* Did not meet goal of cutting risk of disease worsening,
April 12 (Reuters) - Data from a late-stage study to test if
AstraZeneca's diabetes drug Farxiga could treat patients
hospitalised with COVID-19 and at risk of developing serious
complications fell short of its main goals, the drugmaker said
The Farxiga data did not achieve statistical significance in
cutting the risk of the disease worsening and death in such
patients, the Anglo-Swedish drugmaker said.
AstraZeneca has had a rollercoaster ride with its
coronavirus vaccine, as nations restricted its use after
European and British regulators confirmed possible links to rare
However, the company has also been working on developing new
treatments and re-purposing existing drugs to prevent and treat
In the Farxiga study, the drug was given over 30 days in a
global trial of 1,250 patients hospitalised with COVID-19, in
addition to the local standard of care, AstraZeneca said.
Patients in the trial also had a medical history of
hypertension, cardiovascular disease and heart failure, type-2
diabetes or chronic kidney disease.
The trial did not achieve statistical significance for the
main goals of prevention and recovery at 30 days but AstraZeneca
said the safety and tolerability profile was consistent with the
medicine's established safety profile.
One of the company's other treatments is an antibody
cocktail called AZD7442, designed to treat the disease rather
than prevent it as the vaccine aims to do.
The treatment, which is in late-stage trials, is one of
several being developed for COVID-19, including efforts by
rivals Moderna Inc and Eli Lilly.
In March, AstraZeneca said it would supply up to half a
million extra doses of the antibody cocktail to the United
States, building on an October 2020 contract for initial
supplies of 200,000 doses, for a value of $726 million.
Shares were flat in early trading.
(Reporting by Vishwadha Chander in Bengaluru; Editing by
Shounak Dasgupta and Clarence Fernandez)